Newtaxel-A Indications/Uses

Breast Cancer: Docetaxel in combination with doxorubicin is indicated for first line therapy of patients with locally advanced or metastatic breast cancer.
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Non-Small Cell Lung Cancer: Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
Prostate Cancer: Docetaxel in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
Ovarian Cancer: Docetaxel in combination with carboplatin is indicated for the first line therapy of patient with advanced ovarian carcinoma of epithelial.
Head and Neck Cancer: Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Gastric Adenocarcinoma: Docetaxel in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
Esophageal Cancer: Docetaxel is indicated for the treatments of patients with advanced or relapsing esophageal squamous cell carcinoma.